These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 25752711)

  • 41. Microfluidic and lab-on-a-chip preparation routes for organic nanoparticles and vesicular systems for nanomedicine applications.
    Capretto L; Carugo D; Mazzitelli S; Nastruzzi C; Zhang X
    Adv Drug Deliv Rev; 2013 Nov; 65(11-12):1496-532. PubMed ID: 23933616
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
    van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness and Decision Analysis in Clinical Gastroenterology and Hepatology: From Evidence to Informed Decision Making.
    Chhatwal J; Kanwal F
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):459-461. PubMed ID: 29246695
    [No Abstract]   [Full Text] [Related]  

  • 45. Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine.
    Zhang XQ; Xu X; Bertrand N; Pridgen E; Swami A; Farokhzad OC
    Adv Drug Deliv Rev; 2012 Oct; 64(13):1363-84. PubMed ID: 22917779
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Endocytosis of nanomedicines.
    Sahay G; Alakhova DY; Kabanov AV
    J Control Release; 2010 Aug; 145(3):182-95. PubMed ID: 20226220
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety assessment of nanomaterials: implications for nanomedicine.
    Nyström AM; Fadeel B
    J Control Release; 2012 Jul; 161(2):403-8. PubMed ID: 22306428
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Review article: gene therapy in gastroenterology and hepatology.
    Forbes SJ; Hodgson HJ
    Aliment Pharmacol Ther; 1997 Oct; 11(5):823-36. PubMed ID: 9354189
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Targeted nanomedicine in diagnostics and therapy of neurological diseases].
    Bertalan F; László B; Attila V
    Ideggyogy Sz; 2013 May; 66(5-6):155-63. PubMed ID: 23909015
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nanomedicines: addressing the scientific and regulatory gap.
    Tinkle S; McNeil SE; Mühlebach S; Bawa R; Borchard G; Barenholz YC; Tamarkin L; Desai N
    Ann N Y Acad Sci; 2014 Apr; 1313():35-56. PubMed ID: 24673240
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Designing switchable nanosystems for medical application.
    Lehner R; Wang X; Wolf M; Hunziker P
    J Control Release; 2012 Jul; 161(2):307-16. PubMed ID: 22580190
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Applications for site-directed molecular imaging agents coupled with drug delivery potential.
    Wang H; Chen X
    Expert Opin Drug Deliv; 2009 Jul; 6(7):745-68. PubMed ID: 19552614
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nanomedicine: a pharma perspective.
    Brown PD; Patel PR
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(2):125-30. PubMed ID: 25196070
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Liposomal drug delivery systems: from concept to clinical applications.
    Allen TM; Cullis PR
    Adv Drug Deliv Rev; 2013 Jan; 65(1):36-48. PubMed ID: 23036225
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Silicon nanostructures for cancer diagnosis and therapy.
    Peng F; Cao Z; Ji X; Chu B; Su Y; He Y
    Nanomedicine (Lond); 2015; 10(13):2109-23. PubMed ID: 26135645
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Achievements of gastroenterology in the practice of public health].
    Loginov AS
    Ter Arkh; 1974; 46(4):3-5. PubMed ID: 4428364
    [No Abstract]   [Full Text] [Related]  

  • 57. RNAi nanomedicines: challenges and opportunities within the immune system.
    Weinstein S; Peer D
    Nanotechnology; 2010 Jun; 21(23):232001. PubMed ID: 20463388
    [TBL] [Abstract][Full Text] [Related]  

  • 58. From immunotoxicity to nanotherapy: the effects of nanomaterials on the immune system.
    Smith MJ; Brown JM; Zamboni WC; Walker NJ
    Toxicol Sci; 2014 Apr; 138(2):249-55. PubMed ID: 24431216
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inorganic hollow nanoparticles and nanotubes in nanomedicine Part 2: Imaging, diagnostic, and therapeutic applications.
    Son SJ; Bai X; Lee SB
    Drug Discov Today; 2007 Aug; 12(15-16):657-63. PubMed ID: 17706548
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Linking a Hepatology Clinical Service Line to Quality Improvement.
    Fortune BE; Golus A; Barsky CL; Allen JI
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1391-5. PubMed ID: 26194139
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.